BioCentury
ARTICLE | Finance

NEA eyes gene therapy

Why NEA chose NightstaRx for its first gene therapy investment

November 16, 2015 8:00 AM UTC

The key to New Enterprise Associates leading last week's $35 million series B round for NightstaRx Ltd. was transitioning the biotech from a single program to a broader portfolio of gene therapy assets.

David Mott said NEA had been looking for an entry point into gene therapy, particularly in ophthalmology. ...